GeoVax to Present at the 37th Annual Roth Conference

ATLANTA, GA - March 11, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 37th Annual Roth Conference, taking place in Dana Point, CA on March 16-18, 2025. Mr. Dodds presentation will be in the form of a fireside chat moderated by Roth Managing Director, Senior Research Analyst Jonathan Aschoff, PhD.

Presentation Details:

Presenter:

David Dodd, Chairman & CEO

Date/Time:

March 17, 2025, 11:00 am PT

Location:

Dana Point, CA

Webcast Link:

Click Here

The Company will also host in-person investor meetings. Institutional investors wishing to attend the conference and schedule meetings with GeoVax leadership should contact their Roth MKM representative.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin(R) combined with an immune checkpoint inhibitor is planned. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com .

Company Contact:

[email protected]

678-384-7220

Investor Relations Contact:

[email protected]

212-698-8696

Media Contact:

[email protected]

202-779-0929

View the original release on www.newmediawire.com

Copyright 2025 JCN Newswire . All rights reserved.

You May Also Be Interested In

• Dogecoin Price Prediction: DOGE Targets $0.635 in a Bull Cycle as AlphaPepe Builds the Earlier 100x Watchlist Setup
• Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
• TMX Group Completes Acquisition of Cboe Australia